This section covers content and information about CLEARSYNTH published in global publications along with own company press releases.

"Clearsynth adheres to the changing requirements by introducing advanced mechanisms and instruments"

14-17 February 2017
Source: http://www.pharmabioworld.com/vijay_ambati_interview.html

Clearsynth intends to be the catalyst in accelerated discovery via synthesis of complex and difficult to make compounds. The company is dedicatedly developing future molecules to meet the requirements of pharmaceutical industry and targeting new sectors such as enzymes, natural extracts, vitamins, hormones and petrochemicals.” Says Vijay Ambati, President & CEO, Clearsynth. Excerpts from the interview he had with Mahesh Kallayil.

Clearsynth intends to be the catalyst in accelerated discovery

22 December 2016
Source: http://www.expressbpd.com/pharma/ipc/clearsynth-intends-to-be-the-catalyst-in-accelerated-discovery/380240/

Clearsynth is a technology-based, research-driven organisation that specialises in developing certified analytical standards and high-end isotope research chemicals. The company is engaged in synthesis for stable, isotope-labelled compounds, metabolites, impurities, glucuronides, chiral compounds, conjugate impurities and radioactive labelled compounds.



Changing Landscape of Analytical Reference Standards

18 December 2016
Source: https://www.magzter.com/preview/6555/212580#page/4

A Reference Standard is a highly characterized, standardized & validated reference material. They enable the measurement of the sensitivity, specificity & accuracy of assay or workflow.

Beating Bug with Deuterated Drugs

May 2017
Source: Biotalk

The drug modification could address patent cliff, drug shortages, high costs and chronic disorders issues.



Elsevier and Bio-organic - Medicinal Chemistry Letters

Clearsynth is proud to share our recent publications at Elsevier and Bio-organic - Medicinal Chemistry Letters. Congratulating Dr. Naveen for his two latest research publication on medicinal chemistry. Dr. Naveen has worked on synthesis of Quinazolinones alkaloids which have been researched for myraids of applications in pharma. This paper appeared in international journal Elsevier. His second paper for determining anticancer activity of piperazine derivatives was published in Bioorganic & Medicinal Chemistry Letters.

Flow Chemistry Symposium & Workshop

16-17 June 2016
at IICT, Hyderabad, India

Clearsynth Labs Ltd is sponsoring 2nd FCS Symposium & Workshop 2016 "Flow in India" at IICT, Tarnaka. Recently, application of the flow technologies for the preparation of Active Pharmaceutical Ingredients (APIs), has become very popular, especially in academia. However pharma industry still relies on multipurpose batch or semibatch reactors, so this is a symposium arranged to propagate the concepts of flow chemistry into industry. In this symposium Experts in this field like Dr. Charlotte Wiles, Prof. Anil Kumar, Dr. Vijay Kirpalani, Mr. Manjinder singh, Mr. Gabor Rozipal and Dr. Kevin van Eeten are delivering their lectures.



Cushman & Wakefield, featuring our Canadian Lab operations!

August 11, 2015
Source: http://www.flipdocs.com/showbook.aspx?ID=10007901_908115&P=2

By Randolph W. Borron, Vice Chairman & Canadian Lead,
Life Science Practice Group, Cushman & Wakefield.
Updated on: August 11, 2015

CLEARSYNTH OPENS LAB IN MISSISSAUGA
Clearsynth is a technology based research driven enterprise, offering integrated products and services in Reference Standards; Stable Isotope Labeled Compounds, Metabolites, Impurities, Chiral Compounds and other related products. Currently headquartered in Mumbai, India, with its laboratory in Hyderabad, Clearsynth was seeking to set up a base for its North American operations in Canada.

Brand Equity Lessons At CPhI Worldwide From "Rx India"

16-Oct-2014
Source:
http://www.outsourcedpharma.com

By Louis Garguilo,
Executive Editor,
Outsourced Pharma

Updated on: 17th Oct 2014

In another hall, a different kind of Indian service provider, Clearsynth, was demonstrating brand differentiation. Vijay Ambati, chairman & CEO, told me he defines his company as the "'Catalyst' in making global drug discovery research work better for the pharmaceutical industry."



The reference for the world's research chemicals

2-Oct-2014
Source: Japan Times


Updated on: 7th Oct 2014

"People go to Google when they need infomation," say Vijay Kumar Ambati, president and CEO of Clearsynth. "A book seaker goes to Amazon. Similarly we want researcher to acess Clearsynth for their needs." Already, the technology based research-driven company has created the world largest inventory of over 359,000 refrence and research chemicals: globally available on click of a mouse.

Pharma Awards 2013
Emerging Entrepreneur of the Year (Mr.Vijay Kumar Ambati, President & CEO - CLEARSYNTH)

2-Dec-2013

Updated on: 7th Dec 2013

Desh Bandhu Gupta, chairman, Lupin Laboratories was awarded the Lifetime Achievement Award and Vijay Kumar Ambati from Clearsynth was conferred with Emerging Entrepreneur of the Year Award.